news details |
|
|
| Forest fire triggers mine blasts along LoC in Poonch | | |
EARLY TIMES REPORT
POONCH, Oct, 23: Aforest fire triggered several mine blasts along the Line of Control in Jammu and Kashmir’s Poonch district on Friday, officials said. The fire broke out in Balakot sector and spread to few adjoining areas, they said. Some anti-personnel mines exploded due to the fire, triggering panic among the residents, the officials said. The blaze was brought under control by Army and forest department personnel within a few hours, they said. The Bharat Biotech will be conducting Phase 3 trials for its Covid-19 vaccine candidate, COVAXIN, in 25 centres across India and a total of 26,000 people will be participating in the Phase 3 trials.
The Drug Controller General of India (DGCI) has already granted Bharat Biotech a go ahead for the Phase 3 trials after successful completion of Phase 1 and 2 clinical trials. However, the permission for the Phase 3 trials of COVAXIN is subject to minor changes in the primary efficacy endpoint for the symptomatic cases. The primary efficacy endpoint is the outcome by which the effectiveness of treatments in a clinical trial is evaluated. A carefully chosen endpoint can ensure no bias. A primary efficacy endpoint needs to be specified before the start of the clinical trial. “The firm has presented their data from Phase I and II along with animal challenge data in two species including NHP on the Inactivated Corona Virus Vaccine (BBV152) along with the proposal to conduct event-driven Phase III clinical trial to assess the efficacy of the vaccine,” the expert panel of Subject Expert Committee (SEC) said. Developed by Bharat Biotech along with the Indian Council of Medical Research and National Institute of Virology, Covaxin was India’s first indigenous vaccine candidate against the Covid-19. |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| |
|
|
|
|
 |
|
|
